Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE)
- Previous Close
82.80 - Open
83.42 - Bid 83.60 x 400
- Ask 83.66 x 400
- Day's Range
82.83 - 84.04 - 52 Week Range
69.04 - 89.87 - Volume
163,442 - Avg. Volume
194,093 - Net Assets 1.28B
- NAV 83.63
- PE Ratio (TTM) 28.58
- Yield 0.85%
- YTD Daily Total Return -1.01%
- Beta (5Y Monthly) 1.06
- Expense Ratio (net) 0.35%
The fund, under normal circumstances, invests at least 80% of its assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index. The index is the equal weighted version of the NASDAQ-100 Index® which includes approximately 100 of the largest domestic and international non-financial companies listed on the NASDAQ® Stock Market based on market capitalization. The fund is non-diversified.
Direxion Funds
Fund Family
Large Growth
Fund Category
1.28B
Net Assets
2012-03-21
Inception Date
Performance Overview: QQQE
Trailing returns as of 4/22/2024. Category is Large Growth.
People Also Watch
Holdings: QQQE
Top 10 Holdings (10.75% of Total Assets)
Sector Weightings
Recent News: QQQE
Research Reports: QQQE
Daily – Vickers Top Buyers & Sellers for 04/19/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetAnalyst Report: Block, Inc.
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.
RatingPrice TargetAnalyst Report: Block Inc.
Block, which changed its name from Square in late 2021, is a technology platform company that provides payment and point-of-sale solutions to merchants worldwide. While changing its name, Block retained many of its well-known product titles, including its Square terminals. The company provides merchants with hardware for sales and payment solutions, along with software that converts iPads to payment terminals. Payments can be made on Square terminals via a tap, dip, or swipe, or through the company's Block Cash electronic tender. Block also provides CashApp, which allows consumers to send, spend, and store money on an app. Block processes transactions in the U.S. and internationally.
RatingPrice Target